Last reviewed · How we verify
Lipofundin MCT
Lipofundin MCT is a Lipid emulsion for parenteral nutrition Small molecule drug developed by B. Braun Melsungen AG. It is currently FDA-approved for Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition, Provision of essential fatty acids and energy in critically ill or post-operative patients.
Lipofundin MCT is a lipid emulsion that provides essential fatty acids and calories as a component of parenteral nutrition.
Lipofundin MCT is a lipid emulsion that provides essential fatty acids and calories as a component of parenteral nutrition. Used for Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition, Provision of essential fatty acids and energy in critically ill or post-operative patients.
At a glance
| Generic name | Lipofundin MCT |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Drug class | Lipid emulsion for parenteral nutrition |
| Modality | Small molecule |
| Therapeutic area | Nutrition support |
| Phase | FDA-approved |
Mechanism of action
Lipofundin MCT is an intravenous lipid emulsion containing a mixture of medium-chain triglycerides (MCT) and long-chain triglycerides (LCT) designed to supply energy and essential fatty acids to patients unable to receive adequate nutrition orally or enterally. The MCT component is rapidly metabolized and provides quick energy, while the LCT component supplies essential polyunsaturated fatty acids necessary for cellular function and membrane integrity.
Approved indications
- Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition
- Provision of essential fatty acids and energy in critically ill or post-operative patients
Common side effects
- Hypertriglyceridemia
- Infusion site reactions
- Allergic reactions
- Lipemia
Key clinical trials
- The HOME Study (HPN With OMEGA-3) (PHASE4)
- Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study (PHASE2, PHASE3)
- Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants (PHASE2)
- Impact of Fish Oil-enriched Lipid Emulsion on Fatty Acid and Inflammatory Response in Infants After Surgery (NA)
- Lipid Emulsions and Liver Function - Results After 5 Years. (PHASE4)
- Effects of Fat Emulsions on PNALD and Oxidative Stress in Premature Infants (PHASE4)
- Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions (PHASE4)
- Different Lipid Emulsions in Acute Lung Injury Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipofundin MCT CI brief — competitive landscape report
- Lipofundin MCT updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI
Frequently asked questions about Lipofundin MCT
What is Lipofundin MCT?
How does Lipofundin MCT work?
What is Lipofundin MCT used for?
Who makes Lipofundin MCT?
What drug class is Lipofundin MCT in?
What development phase is Lipofundin MCT in?
What are the side effects of Lipofundin MCT?
Related
- Drug class: All Lipid emulsion for parenteral nutrition drugs
- Manufacturer: B. Braun Melsungen AG — full pipeline
- Therapeutic area: All drugs in Nutrition support
- Indication: Drugs for Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition
- Indication: Drugs for Provision of essential fatty acids and energy in critically ill or post-operative patients
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing